Início › Câncer de Bexiga › Carolina do Norte
Ensaios clínicos de Câncer de Bexiga em Carolina do Norte
26 estudos para Câncer de Bexiga estão buscando participantes em locais em Carolina do Norte.
Cidades em Carolina do Norte
Texto oficial do estudo (Inglês)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- AdventHealth Infusion Center Asheville, Asheville
- Southeastern Medical Oncology Center-Clinton, Clinton
- AdventHealth Infusion Center Haywood, Clyde
- e mais 6
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
Idades de 40 a 75 · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT05334069Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT06770582Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Margaret R Pardee Memorial Hospital, Hendersonville
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 30 de set. de 2026 · NCT03866382Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
- Duke Cancer Center Cary, Cary
- Duke University Medical Center (location of scans), Durham
- Duke University Medical Center - Duke University Hospital (location of scans), Durham
- e mais 5
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT07421700A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
- Biorepository and Precision Pathology Center (BRPC), Durham
- Duke Cancer Institute, Durham
- Substrate Services Core Research Support (SSCRS), Durham
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT07206225DESTINY-PANTUMOUR04
- Research Site, Durham
- Research Site, Wilson
RecrutandoEstudo observacional
Idades de 18 a 130 · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT07124000A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
- WakeMed Raleigh Campus ( Site 0811), Raleigh
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT07419295A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
- Levine Cancer Institute, Charlotte
- Oncology Specialists of Charlotte, Charlotte
- Wake Forest Baptist Health, Winston-Salem
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT07218380Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- Carolina Biooncology Institute, Huntersville
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 18 de set. de 2026 · NCT05267626A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
- Duke University Medical Center - Duke Cancer Center, Durham
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 15 de set. de 2026 · NCT07217171ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- UNC- Chapel Hill, Chapel Hill
RecrutandoEstudo observacional
Idades 18 e acima · Todos os sexos · Atualizado em 14 de set. de 2026 · NCT05059444Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
- University of North Carolina, Chapel Hill
- Atrium Health/Levine Center, Charlotte
- Associated Urologist of North Carolina (Solaris), Raleigh
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 3 de set. de 2026 · NCT06567743The Vanguard Study: Testing a New Way to Screen for Cancer
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Durham VA Medical Center, Durham
RecrutandoVoluntários saudáveis bem-vindos
Idades de 45 a 75 · Todos os sexos · Atualizado em 2 de set. de 2026 · NCT06995898FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
- University of North Carolina (UNC) - Chapel Hill, Chapel Hill
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 20 de ago. de 2026 · NCT05614739Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
- Research Site, Chapel Hill
RecrutandoFase 2/3
Idades 18 e acima · Todos os sexos · Atualizado em 20 de ago. de 2026 · NCT07129993Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Duke University Medical Center, Durham
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 18 de ago. de 2026 · NCT07097142LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
- UNC Chapel Hill Hospital, Chapel Hill
- Duke Health - Duke Cancer Center, Durham
- Associated Urologists of North Carolina, Raleigh
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 7 de ago. de 2026 · NCT04752722Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2
- University of North Carolina, Chapel Hill
RecrutandoEstudo observacional
Idades 18 e acima · Todos os sexos · Atualizado em 31 de jul. de 2026 · NCT07225127A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Atrium Health Wake Forest Baptist - Comprehensive Cancer Center, Winston-Salem
RecrutandoFase 2
Idades 8 e acima · Todos os sexos · Atualizado em 27 de jul. de 2026 · NCT05503797A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
- UNC Hospitals, The University of North Carolina at Chapel Hill, Chapel Hill
- UNC Lineberger Comprehensive Cancer Center / University of North Carolina, Chapel Hill
- Carolinas Medical Center (biopsy only), Charlotte
- e mais 10
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 22 de jul. de 2026 · NCT04879329PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
- Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill
Recrutando
Idades 18 e acima · Todos os sexos · Atualizado em 14 de jul. de 2026 · NCT06896162Integrated Cancer Repository for Cancer Research
- Cape Fear Valley Health System, Fayetteville
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
Idades de 19 a 110 · Todos os sexos · Atualizado em 29 de jun. de 2026 · NCT02012699Characterizing the Microvascular Environment of Bladder Cancer With Super-Resolution Ultrasound Localization Microscopy
- Duke University, Durham
RecrutandoEstudo observacional
Idades 18 e acima · Todos os sexos · Atualizado em 4 de mai. de 2026 · NCT06986304Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
- Carolina BioOncology Institute, Huntersville
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 18 de fev. de 2026 · NCT07030257A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
- Duke Cancer Institute, Durham
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 13 de fev. de 2026 · NCT06778863SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Chapel Hill
- Massive Bio SYNERGY-AI site, Winston-Salem
RecrutandoEstudo observacional
Todas as idades · Todos os sexos · Atualizado em 28 de out. de 2025 · NCT03452774Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.